157 related articles for article (PubMed ID: 21839580)
1. Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate.
Lebrun C; Mondot L; Bertagna M; Calleja A; Cohen M
Clin Neurol Neurosurg; 2011 Nov; 113(9):721-4. PubMed ID: 21839580
[TBL] [Abstract][Full Text] [Related]
2. Contribution of endermology to improving indurations and panniculitis/lipoatrophy at glatiramer acetate injection site.
Rubio Fernández D; Rodríguez Del Canto C; Marcos Galán V; Falcón N; Edreira H; Sevane Fernández L; Francoli Martínez P; Sánchez-De la Rosa R
Adv Ther; 2012 Mar; 29(3):267-75. PubMed ID: 22382874
[TBL] [Abstract][Full Text] [Related]
3. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
[TBL] [Abstract][Full Text] [Related]
4. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate.
Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R
Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757
[TBL] [Abstract][Full Text] [Related]
5. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
6. Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study.
Soares Almeida LM; Requena L; Kutzner H; Angulo J; de Sa J; Pignatelli J
J Am Acad Dermatol; 2006 Dec; 55(6):968-74. PubMed ID: 17097393
[TBL] [Abstract][Full Text] [Related]
7. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
Soós N; Shakery K; Mrowietz U
Am J Clin Dermatol; 2004; 5(5):357-9. PubMed ID: 15554737
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous Side-effects of Immunomodulators in MS.
Lebrun C; Bertagna M; Cohen M
Int MS J; 2011 Sep; 17(3):88-94. PubMed ID: 21689492
[TBL] [Abstract][Full Text] [Related]
9. Contact dermatitis induced by glatiramer acetate.
Haltmeier S; Yildiz M; Müller S; Anliker MD; Heinzerling L
Mult Scler; 2011 Nov; 17(11):1390-2. PubMed ID: 21729979
[TBL] [Abstract][Full Text] [Related]
10. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Hawkins C;
J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
[TBL] [Abstract][Full Text] [Related]
11. Lobular panniculitis and lipoatrophy of the thighs with interferon-ß1a for intramuscular injection in a patient with multiple sclerosis.
Weise G; Hupp M; Kerstan A; Buttmann M
J Clin Neurosci; 2012 Sep; 19(9):1312-3. PubMed ID: 22721889
[TBL] [Abstract][Full Text] [Related]
12. Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Carotenuto A; Iodice R; Barbato F; Orefice NS; Orefice G
J Neurol Sci; 2013 Aug; 331(1-2):172-3. PubMed ID: 23778027
[TBL] [Abstract][Full Text] [Related]
13. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
[TBL] [Abstract][Full Text] [Related]
15. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
Bains SN; Hsieh FH; Rensel MR; Radojicic C; Katz HT; Inamdar SR; Lang DM
Ann Allergy Asthma Immunol; 2010 Apr; 104(4):321-5. PubMed ID: 20408342
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer: new preparation. No place in multiple sclerosis.
Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
[TBL] [Abstract][Full Text] [Related]
18. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S;
Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058
[TBL] [Abstract][Full Text] [Related]
19. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
[TBL] [Abstract][Full Text] [Related]
20. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]